Robust method for TALEN-edited correction of pF508del in patient-specific induced pluripotent stem cells

Area of Science:

• Biotechnology
• Genetics
• Regenerative Medicine

Background:

• Cystic fibrosis is a common inherited rare disease caused by CFTR gene mutations.
• Current treatments are symptomatic, lacking a cure for the underlying genetic defect.

Purpose of the Study:

• To present an efficient method for seamless correction of the pF508del mutation in patient-specific induced pluripotent stem cells (iPSCs).
• To establish a robust stem cell and genetic therapy approach for cystic fibrosis treatment.

Main Methods:

• Utilized gene editing via transcription activator-like effector nucleases (TALENs) and homologous recombination.
• Employed a donor vector with a PiggyBac transposon-based double selectable marker for precise gene correction.
• Implemented a robust culture system to enhance cell culture efficiency and genome stability, minimizing xenobiotics.

Main Results:

• Achieved seamless correction of the pF508del mutation in patient-derived iPSCs.
• The entire procedure, from cell amplification to correction, can be completed within 69 days.
• The method demonstrated adaptability for editing various genes of interest.

Conclusions:

• This efficient gene editing technique provides a viable strategy for correcting CFTR mutations in patient-derived iPSCs.
• The developed method supports the development of future stem cell-based therapies for cystic fibrosis.
• The protocol is adaptable for broader gene editing applications in research and potential therapeutic development.